[Cytomegalovirus disease in immunosuppressed patients with necrotizing pauci-immune glomerulonephritis].

Autor:	Barroso Hernández S; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España. Electronic address: sbarrosoh@senefro.org., Rodríguez Sabillón JA; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Álvarez López Á; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., García de Vinuesa Calvo E; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Calvo Cano A; Unidad de Patología Infecciosa, Hospital Universitario de Badajoz, Badajoz, España., Robles Pérez-Monteoliva NR; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Medicina clinica [Med Clin (Barc)] 2023 Mar 10; Vol. 160 (5), pp. 199-202. Date of Electronic Publication: 2022 Aug 26.
DOI:	10.1016/j.medcli.2022.07.009
Abstrakt:	Introduction: Renal involvement due to necrotizing pauci-immune glomerulonephritis (PIGN) associated with small vessel vasculitis requires the use of immunosuppressive. Associated side effects include an increased risk of infectious processes, such as cytomegalovirus (CMV) disease; therefore, there are no recommendations on its management in the various clinical practice guidelines (CPG). Objective: To study the incidence of CMV disease and its determinants. Patients and Methods: Patients with histological diagnosis of necrotizing pauci-immune glomerulonephritis in the last 10 years, who were determined the viral load of CMV, analyzing the determinants of its occurrence. Results: Forty-four biopsies were performed during the study period. Eleven patients (25%) developed CMV disease; all had received immunosuppressive treatment. Four (30.8%) died during admission. The determinants of CMV disease were age (for every 10 years OR: 3.0, 95% CI: 1.0-8.9, p = 0.012), and plasma albumin (for each g/L OR: 0.8, 95% CI: 0.6-1.0, p = 0.012). Conclusions: The incidence of CMV disease in immunocompromised patients due to PIGN is high, with high mortality. It would be necessary to include strategies in the CPGs to prevent it. (Copyright © 2022 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu